Physician profile
Fang Chen
NPI 1407193790
$302.35
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.51 · 2020: $177 · 2021: $73.07 · 2022: $26.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $62.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.41 | 2020-2021 | |
| Abbvie INC. | $44.44 | 2021-2022 | |
| Csl Behring | $28.96 | 2020 | |
| Allergan, INC. | $28.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $25.54 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.52 | 2020-2021 | |
| Amgen INC. | $22.32 | 2020 | |
| Pfizer INC. | $15.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.